MK5684-004 Phase 3, Randomized Study of MK-5684 vs alternative aberatarone acetate or enzalutamide in participants with metastatic castration resistant prostate cancer that progressed on or after prior treatment with one next-generation hormonal agent



Mary Beth Wilwerding, RN Admin@NEcancertrials.com



Available at Nebraska Cancer Specialists, Omaha and Grand Island, NE locations

Interested in More Information?

Please fill out the form below. Someone will get back to you as soon as possible.

"*" indicates required fields

Name*

Email*

Phone*

Message*